These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 11340581

  • 1. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
    Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F.
    Int J Cancer; 2001 Jun 01; 92(5):738-47. PubMed ID: 11340581
    [Abstract] [Full Text] [Related]

  • 2. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G, Bombardelli E, Zunino F.
    Clin Cancer Res; 2002 Aug 01; 8(8):2647-54. PubMed ID: 12171897
    [Abstract] [Full Text] [Related]

  • 3. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 4. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.
    Kolfschoten GM, Hulscher TM, Duyndam MC, Pinedo HM, Boven E.
    Biochem Pharmacol; 2002 Feb 15; 63(4):733-43. PubMed ID: 11992642
    [Abstract] [Full Text] [Related]

  • 5. Ovarian cancer cisplatin-resistant cell lines: multiple changes including collateral sensitivity to Taxol.
    Perego P, Romanelli S, Carenini N, Magnani I, Leone R, Bonetti A, Paolicchi A, Zunino F.
    Ann Oncol; 1998 Apr 15; 9(4):423-30. PubMed ID: 9636834
    [Abstract] [Full Text] [Related]

  • 6. UV-induced DNA incision and proliferating cell nuclear antigen recruitment to repair sites occur independently of p53-replication protein A interaction in p53 wild type and mutant ovarian carcinoma cells.
    Riva F, Zuco V, Vink AA, Supino R, Prosperi E.
    Carcinogenesis; 2001 Dec 15; 22(12):1971-8. PubMed ID: 11751427
    [Abstract] [Full Text] [Related]

  • 7. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
    Vredenburg MR, Ojima I, Veith J, Pera P, Kee K, Cabral F, Sharma A, Kanter P, Greco WR, Bernacki RJ.
    J Natl Cancer Inst; 2001 Aug 15; 93(16):1234-45. PubMed ID: 11504769
    [Abstract] [Full Text] [Related]

  • 8. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
    Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P, Riva A, Giavazzi R.
    Clin Cancer Res; 2002 Apr 15; 8(4):1182-8. PubMed ID: 11948131
    [Abstract] [Full Text] [Related]

  • 9. Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.
    Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G, Zunino F.
    Prostate; 2001 Sep 15; 48(4):254-64. PubMed ID: 11536305
    [Abstract] [Full Text] [Related]

  • 10. Induction of apoptosis and stress response in ovarian carcinoma cell lines treated with ST1926, an atypical retinoid.
    Zuco V, Zanchi C, Cassinelli G, Lanzi C, Supino R, Pisano C, Zanier R, Giordano V, Garattini E, Zunino F.
    Cell Death Differ; 2004 Mar 15; 11(3):280-9. PubMed ID: 14657960
    [Abstract] [Full Text] [Related]

  • 11. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.
    Gynecol Oncol; 2002 Mar 15; 84(3):404-12. PubMed ID: 11855878
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
    Gallo D, Ferlini C, Distefano M, Cantelmo F, Gaggini C, Fattorossi A, Riva A, Bombardelli E, Proietti E, Mancuso S, Scambia G.
    Cancer Chemother Pharmacol; 2000 Mar 15; 45(2):127-32. PubMed ID: 10663627
    [Abstract] [Full Text] [Related]

  • 13. IDN 5390: an oral taxane candidate for protracted treatment schedules.
    Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F.
    Br J Cancer; 2003 Mar 24; 88(6):965-72. PubMed ID: 12644838
    [Abstract] [Full Text] [Related]

  • 14. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
    Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN.
    Cancer Res; 1999 Aug 01; 59(15):3663-70. PubMed ID: 10446979
    [Abstract] [Full Text] [Related]

  • 15. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 16. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC, Zunino F.
    Clin Cancer Res; 1997 Jun 15; 3(6):955-61. PubMed ID: 9815771
    [Abstract] [Full Text] [Related]

  • 17. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53.
    Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C.
    Mol Pharmacol; 1998 May 15; 53(5):819-26. PubMed ID: 9584207
    [Abstract] [Full Text] [Related]

  • 18. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
    Righetti SC, Perego P, Corna E, Pierotti MA, Zunino F.
    Cell Growth Differ; 1999 Jul 15; 10(7):473-8. PubMed ID: 10437915
    [Abstract] [Full Text] [Related]

  • 19. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
    Petrangolini G, Cassinelli G, Pratesi G, Tortoreto M, Favini E, Supino R, Lanzi C, Belluco S, Zunino F.
    Br J Cancer; 2004 Apr 05; 90(7):1464-8. PubMed ID: 15054472
    [Abstract] [Full Text] [Related]

  • 20. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
    Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T.
    Biochem Pharmacol; 2001 Dec 01; 62(11):1469-80. PubMed ID: 11728383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.